We demonstrate that these bi-transgenic mouse severity models recapitulate many aspects of FSHD pathophysiology, thus providing suitable models for therapeutic interventions targeting DUX4-fl mRNA, protein, and potentially certain downstream pathways, with several key caveats. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.